Fig. 1: Analysis of anti-HCV and anti-HBV activities of iCDM-17 and -34. | Cell Death Discovery

Fig. 1: Analysis of anti-HCV and anti-HBV activities of iCDM-17 and -34.

From: A small molecule iCDM-34 identified by in silico screening suppresses HBV DNA through activation of aryl hydrocarbon receptor

Fig. 1

Chemical structure of iCDM-17 (A) and iCDM-34 (B). HCV replicon cells were treated with 0.05–30 µM iCDM-17 (C) and iCDM-34 (D) for 3 days, and luciferase intensity (blue bars) and cell viability (gray lines) were measured. Primary human hepatocytes were infected with HBV genotype C and cultured for 28 days, and then treated with 0.03–100 µM iCDM-17 (E) and iCDM-34 (F) for 7 days. Cell viability was measured using the XTT assay kit (gray lines), and cellular HBV DNA levels were measured by qPCR (blue bars). Error bars indicate SD (n = 3).

Back to article page